Skip to main content
. 2016 Nov 24;8(1):1007–1022. doi: 10.18632/oncotarget.13537

Figure 2. Identification and validation of compounds that exhibit selective inhibitory effects on HMLER-shEcad spheres.

Figure 2

A. Three groups of active compounds with related chemical core structures were identified: Group 1: deptropine (Prestw-1013: deptropine citrate) and benztropine (NSC42199/Prestw-1236: benztropine mesylate); Group 2: adrenosterone (Prestw-899) and tomatidine (NSC27592); Group 3: aripiprazole (Prestw-1229) and ketoconazole (Prestw-389) B. Dose-response curves of HMLE spheres and HMLER-shEcad spheres treated with selected compounds. C. Cell viability of MDA-MB-231 spheres treated with different concentrations of deptropine citrate and benztropine mesylate for 72 h. Data are expressed as mean±SD.